Establishes "Medicaid Pharmacy Benefit Transparency and Accountability Act."

2026-2027 Regular Session Introduced by Heather Simmons

Nebraska? Wait bill is New Jersey A-5388: mandates transparent reporting on Medicaid drug pricing, rebates, and utilization to improve oversight and control costs.

Summary of Bill A-5388 (Session 222, New Jersey)

Purpose and intent

Establishes the Medicaid Pharmacy Benefit Transparency and Accountability Act.

The bill aims to increase transparency, accountability, and oversight of prescription drug benefits within New Jersey’s Medicaid program.

Key provisions and changes

Transparency requirements:

Mandates reporting by Medicaid managed care organizations and/or the state Medicaid program on pharmaceutical pricing, rebates, and utilization.
Requires disclosure of negotiated drug prices, rebates, and any differential pricing strategies affecting the Medicaid program.

Accountability measures:

Creates mechanisms to monitor and evaluate the cost impact of pharmacy benefits on the Medicaid budget.
Establishes procedures to identify and address price-spiking, excessive rebates, or other practices that may raise costs to the program.

Reporting and data access:

Specifies what data must be collected, how it must be reported, and to whom the information must be available (e.g., state officials, legislative committees, or possibly the public in aggregated form).
May require periodic public reporting or legislative briefing on Medicaid drug spending and savings achieved through preferred drug lists, prior authorization, and formulary management.

Oversight and enforcement:

Creates or authorizes oversight bodies or officers within the state health department or a related agency to ensure compliance with transparency requirements.
Establishes potential penalties or corrective actions for entities that fail to comply with reporting or disclosure obligations.

Affected parties

Medicaid beneficiaries and enrollees:

Potential indirect effects through increased transparency and potential program savings that could influence benefits or enrollees’ access to affordable medications.

State agencies and contractors:

Department of Health or Department of Human Services, Medicaid program administrators, and managed care organizations participating in Medicaid.

Pharmaceutical manufacturers and wholesalers:

Subject to greater visibility into pricing, rebates, and discounts within the Medicaid program.

Legislative bodies:

Receive regular data and updates to inform policymaking and potential further reform.

Procedural and timeline aspects

The bill would establish effective dates and deadlines for reporting requirements, data submission, and any phased implementation.

Likely includes a schedule for initial reporting, followed by ongoing annual or quarterly disclosures and annual or biannual reviews by legislative committees.

May authorize rulemaking or guidance to implement the statute, including definitions of key terms (e.g., “rebates,” “net price,” “formulary management”) and data standards.

Potential impact

Increased visibility into how Medicaid drug benefits are priced and managed, enabling policymakers to assess cost drivers and potential savings.

Greater accountability for entities involved in Medicaid pharmacy benefits.

Potential influence on formulary design, rebate negotiations, and overall drug spending within the Medicaid program.

Note: This summary reflects the bill’s stated goals and typical features of transparency and accountability legislation. For exact language, definitions, specific reporting formats, penalties, and implementation dates, please refer to the official bill text and any enacted amendments.